Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–2 of 2 results
Advanced filters: Author: "Sumanta K. Pal" Clear advanced filters

  • An update of the COU-AA-301 study confirms a survival advantage with abiraterone–prednisone compared to prednisone in post-docetaxel patients with metastatic castration-resistant prostate cancer. We place these data in the context of earlier disease states and other novel agents and explore practical issues concerning the future use of abiraterone.

    • Oliver Sartor
    • Sumanta K. Pal
    News & Views
    Nature Reviews Clinical Oncology
    Volume: 10, P: 6-8

  • For nearly two decades, carbonic anhydrase IX (CAIX) expression has been investigated as a prognostic marker in renal cell carcinoma (RCC). During this time, CAIX-directed treatments have emerged, including 177Lu-labelled girentuximab. A small phase II study highlights modest efficacy and a concerning safety profile associated with this compound in patients with metastatic RCC.

    • Sumanta K. Pal
    • Neeraj Agarwal
    News & Views
    Nature Reviews Urology
    Volume: 13, P: 442-443